A betahistine sublingual immediate-release drug composition, its preparation method and application

By using super-disintegrants, bioadhesives, mucosal permeability enhancers, and alkaline pH buffers in the sublingual immediate-release drug composition of betahistine, the pH of the sublingual microenvironment is regulated, thus solving the problem of low sublingual absorption efficiency of betahistine and achieving rapid disintegration and efficient absorption, meeting the clinical needs of acute vertigo attacks.

CN123059010APending Publication Date: 2026-11-10JIUHUA HUAYUAN PHARMACEUTICAL CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611411511.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-11
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing oral betahistine formulations have slow onset of action, low bioavailability, significant first-pass effect, serious gastrointestinal adverse reactions, and insufficient sublingual mucosal absorption efficiency, failing to meet the need for immediate relief of acute vertigo attacks.

Method used

Sublingual immediate-release drug compositions were prepared using superdisintegrants, bioadhesives, mucosal permeability enhancers, and alkaline pH buffers via direct powder compression or lyophilization. The pH of the sublingual microenvironment was adjusted to 7.5–9.0 to increase the proportion of drug molecules and promote passive diffusion.

Benefits of technology

It achieves ultra-rapid disintegration and efficient sublingual absorption of betahistine, avoids first-pass metabolism in the liver, significantly improves bioavailability, and meets the need for immediate relief of acute dizziness attacks.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

This invention discloses a sublingual immediate-release drug composition for betahistine, comprising betahistine or a pharmaceutically acceptable salt thereof, a superdisintegrant or lyophilized matrix support, a bioadhesive, a mucosal permeability enhancer, an alkaline pH buffer, and other pharmaceutical excipients. It can be prepared in two dosage forms: direct powder tablets (disintegration ≤60s) and lyophilized films (disintegration ≤15s). Addressing the high pKa (9.7) characteristic of betahistine's secondary amine nitrogen, an alkaline buffer system is used to adjust the pH of the sublingual microenvironment to 7.5-9.0, increasing the proportion of non-ionized molecular states of the drug. Combined with a mucosal permeability enhancer to improve transmembrane permeability and a bioadhesive to prolong mucosal retention time, this effectively solves the problem of low sublingual absorption efficiency for high pKa, weakly alkaline drugs. This formulation achieves effective blood drug concentrations within 5-15 minutes after sublingual administration, avoiding the first-pass effect of the liver, and is suitable for immediate treatment of acute attacks of vestibular system diseases such as Meniere's disease and vestibular neuritis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical formulation technology, and particularly relates to a betahistine sublingual immediate-release drug composition, its preparation method and application. Background Technology

[0002] Betahistine is a first-line drug for the treatment of Meniere's disease and related vertigo. It dilates blood vessels in the inner ear, improves microcirculation in the inner ear, and regulates the excitability of the vestibular nuclei by activating histamine H1 receptors and antagonizing H3 receptors.

[0003] Betahistine is a weakly basic drug containing two basic nitrogen atoms in its molecule: pyridine nitrogen (pKa1≈3.5) and aliphatic secondary amine nitrogen (pKa2≈9.7). Currently available commercial formulations are mainly oral tablets (betahistine hydrochloride tablets and betahistine mesylate tablets), which have the following prominent problems: 1. Slow onset of action, unable to meet the needs of acute attacks. Oral tablets need to be absorbed by the gastrointestinal tract and metabolized by the liver before they can exert their effects. The time to peak effect (Tmax) is usually 1 to 2 hours, which cannot meet the clinical need for immediate relief during acute attacks of vertigo.

[0004] 2. Significant first-pass effect and extremely low bioavailability. Although betahistine is rapidly and almost completely absorbed from the gastrointestinal tract after oral administration, it is extensively metabolized by monoamine oxidase B (MAO-B) in the intestinal mucosa and liver. The absolute bioavailability of the parent drug is less than 1%, with large individual variability, affecting the stability and predictability of efficacy. Studies have shown that the combined use of the MAO-B inhibitor selegiline can increase the oral bioavailability of betahistine by 80 to 108 times, directly demonstrating that first-pass metabolism is the main bottleneck to bioavailability.

[0005] 3. Gastrointestinal adverse reactions and poor compliance. Common adverse reactions of oral betahistine include nausea, stomach discomfort, and decreased appetite; while acute attacks of vertigo are often accompanied by nausea and vomiting, resulting in extremely poor patient compliance with oral medication, and even drug loss and dosage uncertainty due to vomiting.

[0006] 4. Membrane permeability is not a bottleneck, but ionization is high at pH. The apparent permeability coefficient of betahistine's Caco-2 is approximately 12~13×10⁻⁶. -6 The drug has a permeability of cm / s and is classified as a medium- to high-permeability drug. However, due to its pKa of approximately 9.7, the aliphatic secondary amine group is highly ionized (non-ionization fraction <0.5%) at the physiological salivary pH (6.2~7.6). Drug molecules, which are mainly in ionic form, have difficulty penetrating the lipid membrane barrier through passive diffusion, which is the main limiting factor for sublingual mucosal absorption.

[0007] Sublingual mucosal administration is an ideal route to bypass the first-pass effect and achieve rapid onset of action. The sublingual mucosa is thin and richly vascularized, allowing drugs to directly enter the systemic circulation through the internal jugular vein after absorption, effectively avoiding first-pass metabolism in the gastrointestinal tract and liver. However, betahistine, as a high pKa weakly basic drug, has an extremely low non-ionization rate at physiological pH. Improving its sublingual mucosal penetration efficiency is a key technical challenge in formulation development.

[0008] Among existing patents, CN110664765A discloses a betahistine sublingual tablet using a conventional wet granulation and tableting process. However, this solution has the following shortcomings: (1) It does not optimize the formulation for ultra-rapid disintegration, and the disintegration time usually exceeds 2 minutes; (2) It does not contain a mucosal penetration enhancer, resulting in limited sublingual absorption efficiency; (3) It does not involve pH buffering technology and does not improve the proportion of drug molecules by alkalizing the sublingual microenvironment to promote passive diffusion; (4) It does not provide a lyophilized sublingual film tablet form, making it impossible to achieve disintegration within 15 seconds.

[0009] CN101797237A discloses betahistine mesylate orally disintegrating tablets, but they are designed to be swallowed after disintegration in the oral cavity for absorption in the gastrointestinal tract. They are not optimized for absorption under the tongue mucosa, do not contain permeability enhancers or bioadhesives, and cannot avoid the first-pass effect.

[0010] Therefore, there is still a need in the field for a betahistine sublingual immediate-release formulation that disintegrates rapidly (≤60 seconds, preferably ≤15 seconds), is highly efficient in sublingual mucosal absorption, effectively avoids the first-pass effect, and takes effect immediately in acute attacks. Summary of the Invention

[0011] The purpose of this invention is to overcome the shortcomings of the prior art and provide a betahistine sublingual immediate-release drug composition, its preparation method, and its application. Ultra-rapid disintegration of the sublingual immediate-release drug is achieved through a superdisintegrant (or lyophilized porous structure); sublingual localization and adhesion are achieved through a bioadhesive; transmembrane absorption is enhanced through a mucosal permeability enhancer; and the sublingual microenvironment is alkalized through an alkaline pH buffer system to increase the proportion of weakly basic drug molecules and promote passive diffusion, thereby achieving immediate drug delivery and rapid onset of action during acute attacks of vertigo.

[0012] To achieve the above objectives, the technical solution adopted by the present invention includes: In a first aspect, the present invention provides a betahistine sublingual immediate-release pharmaceutical composition, the composition comprising betahistine sublingual immediate-release tablets and / or betahistine lyophilized sublingual immediate-release films; The betahistine sublingual immediate-release tablets comprise the following components by weight percentage: (a) 2-20% of an active ingredient, said active ingredient comprising betahistine or a pharmaceutically acceptable salt thereof, said salt being selected from mesylate, hydrochloride or a combination thereof; (b) 5-30% of a superdisintegrant, wherein the superdisintegrant comprises at least one of crospovidone, crospovidone sodium carboxymethyl cellulose and low-substituted hydroxypropyl cellulose; (c) 30-80% water-soluble filler, wherein the water-soluble filler includes at least one of mannitol, xylitol, maltitol, lactose and microcrystalline cellulose; (d) 1-15% of a bioadhesive, wherein the bioadhesive comprises at least one of carbomer, sodium hyaluronate, xanthan gum, sodium alginate and sodium carboxymethyl cellulose; (e) 0.5-10% of a mucosal permeability enhancer, wherein the mucosal permeability enhancer comprises at least one of poloxamer, sodium deoxycholate, lecithin, and azone; (f) pH buffer 0.5~10%, wherein the pH buffer is an alkaline buffer system; The betahistine lyophilized sublingual immediate-release tablets comprise the following components by weight percentage of the solid components: (a) 2-20% of an active ingredient, said active ingredient comprising betahistine or a pharmaceutically acceptable salt thereof, said salt being selected from mesylate, hydrochloride or a combination thereof; (b) 5-20% of a freeze-dried matrix support, wherein the freeze-dried matrix support comprises at least one of gelatin, polyvinyl alcohol, gum arabic, collagen and dextran; (c) 30-75% water-soluble filler, wherein the water-soluble filler includes at least one of mannitol, xylitol, maltitol and lactose; (d) 0.5-10% of a bioadhesive, wherein the bioadhesive comprises at least one of carbomer, sodium hyaluronate, xanthan gum, sodium alginate and sodium carboxymethyl cellulose; (e) 0.5-10% of a mucosal permeability enhancer, wherein the mucosal permeability enhancer comprises at least one of poloxamer, sodium deoxycholate, lecithin, and azone; (f) pH buffer 0.5~10%, wherein the pH buffer is an alkaline buffer system.

[0013] Preferably, the pH buffer is configured such that when the betahistine sublingual immediate-release tablet or betahistine lyophilized sublingual immediate-release film comes into contact with saliva, a microenvironment with a pH of 7.5 to 9.0 can be formed locally under the tongue, more preferably with a pH of 8.0 to 8.5.

[0014] Preferably, the betahistine sublingual immediate-release tablets are prepared by direct powder compression, with a tablet weight of 20-100 mg and a hardness of 10-40 N; the disintegration time of the sublingual immediate-release tablets after sublingual administration does not exceed 60 seconds.

[0015] Preferably, the disintegration time of the betahistine lyophilized sublingual immediate-release tablets after sublingual administration does not exceed 15 seconds.

[0016] Preferably, the active ingredient in the betahistine sublingual immediate-release tablets or betahistine lyophilized sublingual immediate-release films is betahistine mesylate, with a weight percentage of 4-12% (calculated as betahistine free base).

[0017] Preferably, the water-soluble filler in the betahistine sublingual immediate-release tablets or betahistine lyophilized sublingual immediate-release films is mannitol and xylitol, and the weight ratio of mannitol to xylitol is (1~5):1.

[0018] Preferably, the mucosal permeability enhancer in the betahistine sublingual immediate-release tablets or betahistine lyophilized sublingual immediate-release films is poloxamer 188 and sodium deoxycholate, wherein the weight ratio of poloxamer 188 and sodium deoxycholate is (2~6):1, and the total weight percentage is 1~5%.

[0019] Preferably, the bioadhesive in the betahistine sublingual immediate-release tablets or betahistine lyophilized sublingual immediate-release films is carbomer, with a weight percentage of 2-8%.

[0020] Preferably, the pH buffer in the betahistine sublingual immediate-release tablets or betahistine lyophilized sublingual immediate-release films is selected from at least one of sodium bicarbonate, sodium carbonate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, glycerol, arginine, and histidine.

[0021] Preferably, the pH buffer is sodium carbonate and sodium bicarbonate, and the weight ratio of sodium carbonate to sodium bicarbonate is 1:(5~20).

[0022] Preferably, the superdisintegrant in the betahistine sublingual tablets is crospovidone and crospovidone sodium carboxymethyl cellulose, wherein the weight ratio of crospovidone to crospovidone sodium carboxymethyl cellulose is (1~3):1, and the total weight percentage is 10~25%.

[0023] Preferably, the lyophilized skeleton support agent in the betahistine lyophilized sublingual immediate-release membrane is gelatin and polyvinyl alcohol, wherein the weight ratio of gelatin to polyvinyl alcohol is (2~5):1, and the total weight percentage is 8~15%.

[0024] Betahistine is a high pKa weakly basic drug, with a pKa of approximately 9.7. Its molecule contains two basic sites: a pyridine nitrogen (pKa1≈3.5) and an aliphatic secondary amine nitrogen (pKa2≈9.7). The pyridine nitrogen is completely ionized at physiological pH and has minimal impact on the drug's lipid solubility; while the aliphatic secondary amine nitrogen is the core site that determines the drug's transmembrane permeability.

[0025] According to the pH partition hypothesis, the passive diffusion ability of drug molecules to penetrate biological membranes is far superior to that of ionic molecules. The pH of normal physiological saliva is 6.2–7.6. Under these conditions, betahistine has an apparent ionization degree exceeding 99.5% and a non-ionization fraction of less than 0.5%, existing almost entirely in an ionic state. Its passive diffusion ability is extremely weak, which is the fundamental reason for the poor absorption efficiency and efficacy of traditional sublingual betahistine formulations. This characteristic is significantly different from that of conventional sublingual drugs such as nitroglycerin (pKa≈6.4) and nifedipine (pKa≈2.3).

[0026] This invention innovatively employs a proprietary pHmax optimization strategy, using an alkaline pH buffer in the prescription to regulate the pH of the sublingual microenvironment to 7.5-9.0 (preferably 8.0-8.5), completely solving the problem of sublingual absorption of high pKa weakly alkaline drugs and achieving optimal balance of efficacy. Its core advantages are as follows: 1. Significantly enhanced osmotic driving force: At pH 8.0, the non-ionized fraction of betahistine is about 2%, which is about 10 times higher than that at physiological pH 7.0; at pH 8.5, the non-ionized fraction is about 6%, which is about 30 times higher. The proportion of molecular drug is significantly increased, and the passive diffusion transmembrane ability is greatly enhanced.

[0027] 2. Balance between solubility and permeability: An increase in the pH of the microenvironment will slightly reduce the solubility of the drug, but within the optimal range of 8.0 to 8.5, betahistine can still maintain an effective solubility at the mg / mL level without drug precipitation, thus balancing dissolution efficiency and permeability efficiency.

[0028] 3. Good mucosal safety: The target pH range is within the tolerance range of the sublingual mucosa. The rabbit sublingual mucosa irritation test verified that there was no obvious irritation or discomfort after short-term contact.

[0029] This pHmax strategy has been clinically validated in sublingual formulations of similar high pKa, weakly basic drugs such as propranolol (pKa 9.4), and can improve drug bioavailability by approximately 3 times. Unlike traditional sublingual formulations that focus solely on "rapid disintegration and enhanced mucosal penetration," this invention adds a core technological dimension of drug-specific pKa-targeted pH microenvironment regulation, fundamentally overcoming technical bottlenecks.

[0030] Furthermore, this invention has specifically developed two sublingual immediate-release formulations of betahistine, suitable for different medication scenarios, both of which can achieve rapid onset of action: 1. Direct-release powder tablets (sublingual): Disintegration time ≤ 60 seconds, stable formula, convenient storage, suitable for daily relief of dizziness symptoms and for home emergency use.

[0031] 2. Freeze-dried sublingual immediate-release film: Disintegration time ≤ 15 seconds, faster onset of action, suitable for acute attacks of severe vertigo.

[0032] The efficacy of each component involved in the aforementioned betahistine sublingual immediate-release formulation is as follows: (1) Active components The active ingredient is betahistine or a pharmaceutically acceptable salt thereof, including betahistine mesylate, betahistine hydrochloride, and combinations thereof, with betahistine mesylate being preferred. Mesylate salts exhibit excellent water solubility, strong chemical stability, and easier penetration of the blood-brain barrier, allowing for precise targeting of the vestibular center and maximizing efficacy. The total active ingredient content, based on betahistine free base, is 2-20%, preferably 4-12%. Combined with standard tablet weights of 20-100 mg, it can be matched to clinical single-dose doses of 6-12 mg, adapting to various production requirements.

[0033] (2) pH buffer A local alkaline buffering microenvironment is constructed under the tongue using a pH buffer to stably maintain a pH of 7.5–9.0 (optimal 8.0–8.5), thereby increasing the proportion of drug molecules and aiding in formulation disintegration and diffusion. The pH buffer is selected from one or more of sodium bicarbonate, sodium carbonate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, glycerol (Tris), arginine, and histidine, preferably a combination of sodium carbonate and sodium bicarbonate in a weight ratio of 1:5–1:20. This buffer pair can precisely stabilize the target pH range, and the carbonate system exhibits a slight effervescent effect, further accelerating formulation disintegration and promoting uniform drug distribution on the sublingual mucosa.

[0034] (3) Superdisintegrant (direct compression only) Superdisintegrants are key components for achieving sublingual rapid release and are selected from one or more of crospovidone (PVPP), crospovidone sodium carboxymethyl cellulose (CCMC-Na), and low-substituted hydroxypropyl cellulose (L-HPC).

[0035] The preferred combination is crospovidone and crospovidone sodium (weight ratio 1:1 to 3:1). Crospovidone absorbs water and swells through an elastic mechanism, while crospovidone sodium rapidly absorbs water through capillary action. Together, they cause the tablet to disintegrate rapidly upon contact with saliva. The total content is 5% to 30%, preferably 10% to 25%. Too low a content results in insufficient disintegration, while too high a content affects tablet hardness and taste.

[0036] (4) Lyophilized skeleton support (lyophilized film type only) The lyophilized support matrix is ​​fundamental to the formation of the porous structure of the lyophilized membrane and is selected from one or more of gelatin, polyvinyl alcohol, gum arabic, collagen, and dextran. A combination of gelatin and polyvinyl alcohol (weight ratio 2:1 to 5:1), with a total content of 5% to 20%, preferably 8% to 15%, is preferred. The gelatin-formed matrix possesses good porous structure and mechanical strength, while polyvinyl alcohol further improves the membrane's formability and flexibility.

[0037] (5) Water-soluble fillers Water-soluble fillers provide good taste and instant solubility, and are selected from mannitol, xylitol, maltitol, lactose, microcrystalline cellulose, etc. (the freeze-dried version does not contain microcrystalline cellulose).

[0038] The preferred combination is mannitol and xylitol (weight ratio 1:1 to 5:1). Mannitol has a cool taste and absorbs heat when dissolved, making it suitable for sublingual administration; xylitol has moderate sweetness and good solubility, which can improve the taste and aid in rapid dissolution.

[0039] (6) Bioadhesives The role of bioadhesives is to allow drug particles to temporarily adhere to the surface of the sublingual mucosa after the formulation disintegrates, thereby increasing the contact area and contact time between the drug and the mucosa and improving absorption efficiency.

[0040] It is selected from carbomer, sodium hyaluronate, xanthan gum, sodium alginate, sodium carboxymethyl cellulose, etc. Carbomer is preferred (2%~8% for direct compression tablets, 1%~5% for lyophilized tablets). Carbomer hydrates in saliva to form a microgel layer, which produces a gentle adhesion to the sublingual mucosa, ensuring that the drug is not swallowed quickly and without causing discomfort.

[0041] (7) Mucosal penetration enhancers Mucosal permeability enhancers are one of the core innovations of this invention. Although the sublingual mucosa has higher permeability than the skin, betahistine is a hydrophilic small molecule drug, and its transmembrane permeation is still limited by the mucosal epithelial barrier.

[0042] It is selected from poloxamer, sodium deoxycholate, lecithin, azone, etc. The preferred combination is poloxamer 188 and sodium deoxycholate (weight ratio 2:1 to 6:1), with a total content of 1% to 6%.

[0043] Poloxamer 188, as a nonionic surfactant, increases the wettability and solubility of the drug on the mucosal surface; sodium deoxycholate, as a bile salt permeation enhancer, reversibly disturbs the intercellular lipid bilayer of the mucosal epithelial cells, opening tight junctions and promoting transcellular permeation. The two work synergistically to significantly increase the sublingual mucosal permeation rate of betahistine. At low concentrations, mucosal irritation is negligible.

[0044] Preferably, the betahistine sublingual immediate-release tablets further contain 0.5% to 8% pharmaceutically acceptable lubricants, flavoring agents, and / or sweeteners.

[0045] Preferably, the betahistine lyophilized sublingual immediate-release film further contains 0.5% to 8% pharmaceutically acceptable flavoring agents and / or sweeteners.

[0046] Secondly, the present invention provides a method for preparing the aforementioned betahistine sublingual immediate-release pharmaceutical composition, wherein the method for preparing the betahistine sublingual immediate-release tablets includes the following steps: (1) Crush and sieve all components, then mix them evenly; (2) The tablets are prepared by direct powder compression method, with the compression pressure controlled at 30~80MPa. The preparation method of the betahistine lyophilized sublingual immediate-release film includes the following steps: (1) Dissolve the lyophilized skeleton support, water-soluble filler and bioadhesive in water for injection and heat to 40~60℃ to dissolve them; (2) After cooling, add the active ingredient, mucosal permeability enhancer and pH buffer, and stir until dissolved to obtain the drug solution; (3) The drug solution is quantitatively dispensed into a mold for freeze drying. After freeze drying, it is sealed and packaged to obtain betahistine freeze-dried sublingual immediate-release film.

[0047] Preferably, in the preparation method of the betahistine lyophilized sublingual immediate-release film, the following lyophilization curve is used for lyophilization: Pre-freezing stage: Cool to -40 to -45℃ at a rate of 1~3℃ / min and maintain for 2~4 hours; First drying stage: Under a vacuum of 10~30Pa, the temperature is increased to -20~-15℃ at a rate of 0.3~0.5℃ / min and maintained for 8~15 hours; Secondary drying stage: Increase the temperature to 25-35℃ at a rate of 0.5-1℃ / min and maintain for 3-6 hours.

[0048] Thirdly, the present invention provides the use of the aforementioned betahistine sublingual immediate-release pharmaceutical composition in the preparation of a medicament for treating vestibular system diseases.

[0049] Preferably, the vestibular system diseases include Meniere's disease, Meniere's syndrome, vestibular neuritis, benign paroxysmal positional vertigo, vestibular migraine, vestibular paroxysmal syndrome, bilateral vestibular disease, motion sickness, labyrinthitis, sudden deafness with vertigo, persistent postural-perceptual dizziness, and vestibular dysfunction.

[0050] Preferably, the drug is administered via the sublingual mucosa, completely disintegrates within 60 seconds, and the active ingredient is directly absorbed into the bloodstream through the sublingual mucosa, bypassing first-pass metabolism in the liver, and reaching an effective blood drug concentration within 5 to 15 minutes after administration.

[0051] Compared with the prior art, the beneficial effects of the present invention are as follows: 1. Specific pHmax Compatibility for Betahistine's High pKa: The core innovation of this invention lies in not simply applying general sublingual immediate-release technology to betahistine, but rather designing a specially formulated alkaline pH buffer system (target microenvironment pH 7.5~9.0, preferably 8.0~8.5) to address the unique physicochemical property of betahistine's secondary amine nitrogen pKa as high as 9.7. This system utilizes a pHmax strategy to find the optimal absorption balance between solubility and permeability. This design increases the proportion of non-ionized molecular state of betahistine under the tongue from <0.5% at physiological pH to ~2% at pH 8.0 (an increase of approximately 10 times) and ~6% at pH 8.5 (an increase of approximately 30 times), fundamentally solving the technical challenge of low sublingual absorption efficiency of high pKa weakly basic drugs. Existing technologies (CN110664765A, CN101797237A, etc.) do not involve pH microenvironment regulation targeting the pKa characteristics of betahistine, which is the key technical feature that distinguishes this invention from general sublingual formulations.

[0052] 2. Three factors work synergistically to form a complete absorption-promoting chain: The pHmax strategy (increasing the proportion of molecular states) + mucosal permeation enhancer (enhancing transmembrane permeability) + bioadhesive (prolonging mucosal retention time) work synergistically to form a complete absorption-promoting chain of "molecular state supply - membrane permeability - retention time". The permeation volume at 15 minutes is 4.1 times that of the blank baseline rapid-disintegrating tablet (total gain +314%) and 4.4 times that of conventional sublingual tablets, which is significantly better than the effect of any single factor.

[0053] 3. Ultra-fast disintegration: The synergistic effect of the super disintegrant (PVPP+CCMC-Na) enables direct-compression tablets to disintegrate in ≤60 seconds, and the lyophilized porous structure enables lyophilized films to disintegrate in ≤15 seconds, both significantly faster than existing sublingual tablets (>120 seconds). Disintegration performance remains stable over a wide content range of 2%~20%.

[0054] 4. Immediate onset of action: Direct absorption through the sublingual mucosa, with a Tmax of only 0.17~0.25h, which is 4~6 times faster than oral tablets (1.0h), meeting the clinical needs for acute attacks of vertigo.

[0055] 5. Improved bioavailability: Effectively avoids first-pass metabolism in the liver, with a relative bioavailability of 176%~198%.

[0056] 6. Two dosage forms cover different scenarios: direct compression tablets (general emergency use) + lyophilized films (disintegrates in seconds for severe acute attacks), meeting the needs of different clinical scenarios.

[0057] 7. Good mucosal safety: The low concentration of the penetration enhancer and the pH buffer system within the physiological tolerance range showed no irritation when repeatedly administered to the rabbit sublingual mucosa over 7 days.

[0058] 8. Stable and feasible process: Direct tableting / freeze-drying are both mature industrial production processes, and all indicators remained stable after 6 months of accelerated testing. Detailed Implementation

[0059] To better illustrate the objectives, technical solutions, and advantages of this invention, the invention will be further described below with reference to specific embodiments. Those skilled in the art should understand that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.

[0060] Unless otherwise specified, all raw materials used in the following examples and comparative examples are commercially available general materials; and all test methods used are conventional methods in the art unless otherwise specified.

[0061] Example 1 This embodiment provides a betahistine mesylate sublingual immediate-release tablet (direct compression method, 6 mg specification), the formulation of which is shown in Table 1.

[0062] Table 1 The preparation process is as follows: 1. Pass betahistine mesylate through a 100-mesh sieve, and pass the remaining excipients through an 80-mesh sieve respectively; 2. Add betahistine mesylate and mannitol in equal increments, mixing for 5 minutes each time; 3. Add xylitol, crospovidone, crospovidone sodium carboxymethyl cellulose, carbomer 974P, poloxamer 188, sodium deoxycholate, sodium carbonate, and sodium bicarbonate in sequence, mixing for 3 minutes after each addition; 4. Add aspartame and menthol and mix for 2 minutes, then add magnesium stearate and mix for 3 minutes. 5. Determine the bulk density and flowability of the mixed powder. Use a direct powder tableting machine with a die diameter of 6 mm, a tableting pressure of 50 MPa, a target tablet weight of 60 mg, and a target hardness of 15~25 N.

[0063] Example 2 This embodiment provides a betahistine mesylate sublingual immediate-release tablet (direct compression method, specification 12mg), the formulation of which is shown in Table 2.

[0064] Table 2 The preparation process is the same as in Example 1, with a die diameter of 8 mm, a pressing pressure of 60 MPa, and a target hardness of 20~30 N.

[0065] Example 3 This embodiment provides betahistine hydrochloride sublingual immediate-release tablets (direct compression method, 6 mg specification), the formulation of which is shown in Table 3.

[0066] Table 3 The preparation process is the same as in Example 1.

[0067] Example 4 This embodiment provides a lyophilized sublingual immediate-release betahistine mesylate film (6 mg), the formulation of which is shown in Table 4.

[0068] Table 4 The preparation process is as follows: 1. Add gelatin to an appropriate amount of water for injection and stir in a 50°C water bath until completely dissolved; 2. Add mannitol, xylitol, and carbomer 974P, and stir to dissolve; 3. Cool to room temperature (25°C), add betahistine mesylate and stir until completely dissolved; 4. Add poloxamer 188, sodium deoxycholate, sodium carbonate, sodium bicarbonate, sucralose, and menthol, stir to dissolve, and add water for injection to the specified volume to obtain the drug solution (0.2 mL / tablet). 5. Dispense the medicine solution into the aluminum-plastic blister mold at a rate of 0.2 mL per well; 6. Freeze-drying curve: Pre-freezing: Cool to -42℃ at 2℃ / min and hold for 3 hours; First drying: Vacuum 15Pa, heat up to -18℃ at 0.3℃ / min and hold for 12 hours; Second drying: Heat up to 30℃ at 0.5℃ / min and hold for 5 hours. 7. After freeze-drying, quickly seal the package with aluminum foil under the protection of dry nitrogen.

[0069] Example 5 This embodiment provides a lyophilized sublingual immediate-release betahistine mesylate film (12 mg), the formulation of which is shown in Table 5.

[0070] Table 5 The preparation process is the same as in Example 4, and the dispensing volume is 0.24 mL / tablet.

[0071] Example 6 This embodiment provides a low-content betahistine mesylate sublingual immediate-release tablet (direct compression method, specification 1.2mg, salt content approximately 2%), the formulation of which is shown in Table 6.

[0072] Table 6 The preparation process is the same as in Example 1, with a die diameter of 6 mm, a pressing pressure of 45 MPa, and a target hardness of 12~20 N.

[0073] Example 7 This embodiment provides a high-content betahistine mesylate sublingual immediate-release tablet (direct compression method, specification 12mg, salt content approximately 20%), the formulation of which is shown in Table 7.

[0074] Table 7 The preparation process is the same as in Example 1, with a die diameter of 6 mm, a pressing pressure of 55 MPa, and a target hardness of 20~35 N.

[0075] Example 8 This embodiment provides a low-content betahistine mesylate lyophilized sublingual immediate-release film (1.2 mg, salt content approximately 2%), the formulation of which is shown in Table 8.

[0076] Table 8 The preparation process is the same as in Example 4, and the dispensing volume is 0.2 mL / tablet.

[0077] Comparative Example 1 This comparative example provides a betahistine mesylate sublingual immediate-release tablet, which differs from Example 1 only in that: no mucosal permeability enhancer (poloxam 188 and sodium deoxycholate) is added, while the remaining components and dosages are consistent with Example 1.

[0078] Comparative Example 2 This comparative example provides a betahistine mesylate sublingual immediate-release tablet, which differs from Example 1 only in that: no pH buffer (sodium carbonate and sodium bicarbonate) is added, while the remaining components and dosages are consistent with Example 1.

[0079] Comparative Example 3 This comparative example provides a betahistine mesylate sublingual immediate-release tablet, which differs from Example 1 only in that: no bioadhesive (carbomer 974P) is added, while the remaining components and dosages are consistent with Example 1.

[0080] Comparative Example 4 This comparative example provides a betahistine mesylate sublingual immediate-release tablet, which differs from Example 1 only in that: it does not contain mucosal penetration enhancers, pH buffers, and bioadhesives (it contains only the active ingredient + filler + disintegrant + lubricant, i.e., a basic immediate-disintegrating tablet), while the remaining components and dosages are consistent with those of Example 1.

[0081] Test Example 1: Disintegration Time Measurement An improved method based on the disintegration time test method in General Chapter 0921 of the Chinese Pharmacopoeia was adopted: The preparation was placed in a petri dish containing 2 mL of artificial saliva (pH 6.8 phosphate buffer, 37℃), and the time for complete disintegration and passage through a sieve was recorded. Specific test results are shown in Table 9.

[0082] Table 9 Table 9 shows that the disintegration time of the direct-compressed formulation of the present invention is 25-38 seconds, and that of the lyophilized film is 6-11 seconds, both significantly shorter than those of the prior art. Within a wide content range of 2%-20%, the disintegration time of the direct-compressed formulation does not exceed 60 seconds, and the disintegration time of the lyophilized film does not exceed 15 seconds, all meeting the technical limitations of the present invention, demonstrating that the formulation design has good dosage adaptability.

[0083] Test Example 2: In vitro mucosal permeability test The Franz diffusion cell method was used, with isolated porcine sublingual mucosa as a barrier. The receiving cell was a pH 7.4 phosphate buffer solution (37°C). The formulations of each example (containing 6 mg of drug) were placed on the supply side. Samples were taken at 5, 10, 15, 30, and 60 minutes, and the cumulative permeation of betahistine in the receiving solution was determined by HPLC. The specific test results are shown in Tables 10-11.

[0084] Table 10 Synergistic Effects of Penetration Enhancers and pH Buffers Table 11 Results of gain analysis for each factor (based on 15-minute cumulative permeability) The results showed that Example 1 achieved a penetration amount of 398.7 μg within 15 minutes, which was 4.4 times that of the prior art 1 (conventional sublingual tablets) and 4.1 times that of the blank control (none of the three).

[0085] When used individually, the permeation enhancer, pH buffer, and bioadhesive increased the absorption rate by 48%, 117%, and 198%, respectively. When used in combination, the total gain reached 314%, demonstrating that the three work synergistically through different mechanisms of action: the pHmax strategy increases the proportion of molecular states, the permeation enhancer opens transmembrane channels, and the bioadhesive prolongs the retention time. The three form a complete absorption promotion chain of "molecular state supply - membrane permeability - retention time".

[0086] Bioadhesives contributed the most (single factor +198%), demonstrating that preventing drug ingestion and prolonging mucosal contact time are key prerequisites for sublingual absorption; pH buffers were the second most effective (+117%), validating the crucial role of the pHmax strategy targeting the high pKa characteristics of betahistine.

[0087] In addition, this test case also tested the effect of pH on osmotic efficiency (pHmax verification). Supply solutions (containing equal amounts of betahistine and the same osmotic enhancer) with pH values ​​of 7.0, 7.5, 8.0, 8.5, and 9.0 were prepared respectively, and the cumulative osmotic volume was measured over 60 minutes. The specific test results are shown in Table 12.

[0088] Table 12 Table 12 shows that the sublingual mucosal permeation efficiency of betahistine first increases and then decreases with increasing pH, reaching a peak (pHmax) at around pH 8.0, consistent with theoretical predictions. At excessively high pH (9.0), the total permeation decreases due to reduced drug solubility. The present invention's selection of a buffer range of pH 7.5–9.0, preferably 8.0–8.5, is scientifically sound and reasonable.

[0089] Test Example 3: Pharmacokinetic Study in Beagle Dogs Six Beagle dogs were randomly assigned to one of the following treatments in a crossover design: ① the formulation from Example 1 (sublingual administration, 6 mg); ② the lyophilized film from Example 4 (sublingual administration, 6 mg); ③ commercially available betahistine mesylate tablets (oral administration, 6 mg). The washout period was 7 days. Blood samples were collected at different time points after administration, and plasma betahistine concentrations were determined by LC-MS / MS. The results are shown in Table 13.

[0090] Table 13 Table 13 shows that the relative bioavailability of Examples 1 and 4 was 1.76 times and 1.98 times that of the commercially available oral tablets, respectively, significantly avoiding the first-pass effect. Furthermore, the Tmax of the lyophilized film of Example 4 was only 0.17 hours (approximately 10 minutes), compared to 0.25 hours (approximately 15 minutes) for Example 1, and 1 hour for the oral tablets, indicating a significantly faster onset of action. In addition, the lyophilized film of Example 4 reached an effective concentration within 5 minutes, meeting the clinical need for immediate relief of acute vertigo attacks.

[0091] Test Example 4: Mucosal Irritation Test The sublingual mucosa irritation test was conducted on New Zealand rabbits using Examples 1 and 4. The medication was administered sublingually twice daily for 7 consecutive days. Sublingual mucosa tissue was collected 24 hours after the last administration for pathological examination. The test results are shown in Table 14.

[0092] Table 14 Table 14 shows that the penetration enhancer and alkaline buffer in the composition of the present invention are non-irritating to the sublingual mucosa within the concentration range and have good safety.

[0093] Test Example 5: Stability Test Examples 1 and 4 were placed at 40°C / 75% RH for 6 months, and samples were taken at 0, 1, 3, and 6 months to examine appearance, content, related substances, and disintegration time. The test results are shown in Table 15.

[0094] Table 15 The results in Table 15 show that the content, related substances, and disintegration time of the formulation of the present invention did not change significantly within 6 months under accelerated test conditions, indicating good stability.

[0095] Finally, it should be noted that the above embodiments are used to illustrate the technical solutions of the present invention and not to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. A betahistine sublingual immediate-release pharmaceutical composition, characterized in that, The composition comprises betahistine sublingual immediate-release tablets and / or betahistine lyophilized sublingual immediate-release films; The betahistine sublingual immediate-release tablets comprise the following components by weight percentage: (a) 2-20% of an active ingredient, said active ingredient comprising betahistine or a pharmaceutically acceptable salt thereof, said salt being selected from mesylate, hydrochloride or a combination thereof; (b) 5-30% of a superdisintegrant, wherein the superdisintegrant comprises at least one of crospovidone, crospovidone sodium carboxymethyl cellulose and low-substituted hydroxypropyl cellulose; (c) 30-80% water-soluble filler, wherein the water-soluble filler includes at least one of mannitol, xylitol, maltitol, lactose and microcrystalline cellulose; (d) 1-15% of a bioadhesive, wherein the bioadhesive comprises at least one of carbomer, sodium hyaluronate, xanthan gum, sodium alginate and sodium carboxymethyl cellulose; (e) 0.5-10% of a mucosal permeability enhancer, wherein the mucosal permeability enhancer comprises at least one of poloxamer, sodium deoxycholate, lecithin, and azone; (f) pH buffer 0.5~10%, wherein the pH buffer is an alkaline buffer system; The betahistine lyophilized sublingual immediate-release tablets comprise the following components by weight percentage of the solid components: (a) 2-20% of an active ingredient, said active ingredient comprising betahistine or a pharmaceutically acceptable salt thereof, said salt being selected from mesylate, hydrochloride or a combination thereof; (b) 5-20% of a freeze-dried matrix support, wherein the freeze-dried matrix support comprises at least one of gelatin, polyvinyl alcohol, gum arabic, collagen and dextran; (c) 30-75% water-soluble filler, wherein the water-soluble filler includes at least one of mannitol, xylitol, maltitol and lactose; (d) 0.5-10% of a bioadhesive, wherein the bioadhesive comprises at least one of carbomer, sodium hyaluronate, xanthan gum, sodium alginate and sodium carboxymethyl cellulose; (e) 0.5-10% of a mucosal permeability enhancer, wherein the mucosal permeability enhancer comprises at least one of poloxamer, sodium deoxycholate, lecithin, and azone; (f) pH buffer 0.5~10%, wherein the pH buffer is an alkaline buffer system.

2. The betahistine sublingual immediate-release pharmaceutical composition as described in claim 1, characterized in that, The pH buffer is configured such that when the betahistine sublingual immediate-release tablet or betahistine lyophilized sublingual immediate-release film comes into contact with saliva, a microenvironment with a pH of 7.5 to 9.0 can be formed locally under the tongue.

3. The betahistine sublingual immediate-release pharmaceutical composition as described in claim 1, characterized in that, The active ingredient in the betahistine sublingual immediate-release tablets or betahistine lyophilized sublingual immediate-release films is betahistine mesylate.

4. The betahistine sublingual immediate-release pharmaceutical composition as described in claim 1, characterized in that, The water-soluble fillers in the betahistine sublingual immediate-release tablets or betahistine lyophilized sublingual immediate-release films are mannitol and xylitol, and the weight ratio of mannitol to xylitol is (1~5):

1.

5. The betahistine sublingual immediate-release pharmaceutical composition as described in claim 1, characterized in that, The mucosal permeation enhancer in the betahistine sublingual immediate-release tablets or betahistine lyophilized sublingual immediate-release films is poloxamer 188 and sodium deoxycholate, and the weight ratio of poloxamer 188 to sodium deoxycholate is (2~6):

1.

6. The betahistine sublingual immediate-release pharmaceutical composition as described in claim 1, characterized in that, The superdisintegrant in the betahistine sublingual immediate-release tablets is crospovidone and crospovidone sodium carboxymethyl cellulose, and the weight ratio of crospovidone and crospovidone sodium carboxymethyl cellulose is (1~3):

1.

7. The betahistine sublingual immediate-release pharmaceutical composition as described in claim 1, characterized in that, The freeze-dried matrix support agent in the betahistine freeze-dried sublingual immediate-release membrane is gelatin and polyvinyl alcohol, and the weight ratio of gelatin to polyvinyl alcohol is (2~5):

1.

8. The method for preparing the betahistine sublingual immediate-release pharmaceutical composition as described in claim 1, characterized in that, The preparation method of the betahistine sublingual immediate-release tablets includes the following steps: (1) Crush and sieve all components, then mix them evenly; (2) The tablets are prepared by direct powder compression method, with the compression pressure controlled at 30~80MPa. The preparation method of the betahistine lyophilized sublingual immediate-release film includes the following steps: (1) Dissolve the lyophilized skeleton support, water-soluble filler and bioadhesive in water for injection and heat to 40~60℃ to dissolve them; (2) After cooling, add the active ingredient, mucosal permeability enhancer and pH buffer, and stir until dissolved to obtain the drug solution; (3) The drug solution is quantitatively dispensed into a mold for freeze drying. After freeze drying, it is sealed and packaged to obtain betahistine freeze-dried sublingual immediate-release film.

9. The use of the betahistine sublingual immediate-release pharmaceutical composition according to any one of claims 1-7 in the preparation of a medicament for treating vestibular system disorders.

10. The application as described in claim 9, characterized in that, The vestibular system disorders include Meniere's disease, Meniere's syndrome, vestibular neuritis, benign paroxysmal positional vertigo, vestibular migraine, vestibular paroxysmal syndrome, bilateral vestibular disease, motion sickness, labyrinthitis, sudden deafness with vertigo, persistent postural-perceptual dizziness, and vestibular dysfunction.

Citation Information

Patent Citations

  • Betahistine mesilate orally disintegrating tablet and preparation method thereof

    CN101797237A

  • Betahistine sublingual lozenge as well as preparation method and application thereof

    CN110664765A